Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP Chief Technology Officer | November 09, 2023 | November 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date November 09, 2023 · Filed November 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,725 |
Reported balance
After 2023-11-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-11-09 · Sale · Disposed 2,725 · Balance 47,725 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 42,363 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 23,587 of which were granted on November 8, 2022 and shall vest through November 8, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 42,363 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 23,587 of which were granted on November 8, 2022 and shall vest through November 8, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2023 Filed Nov 28, 2023 00:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,725 | $93.27 | $254,160.75 |
DisclosureSEC source: 0001093557-23-000236 · edgardoc.xml · nonDerivative · entry 1 Naganathan Girish · CIK 0001949138 · EVP Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,725 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 42,363 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 23,587 of which were granted on November 8, 2022 and shall vest through November 8, 2026. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 20:59 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 18,776 | $0.00 | $18.78 |
DisclosureSEC source: 0001093557-23-000053 · edgardoc.xml · nonDerivative · entry 1 Naganathan Girish · CIK 0001949138 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,225 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 50,225 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 31,449 of which were granted on November 8, 2022 and shall vest through November 8, 2026. Read SEC document |
| November 08, 2022 Filed Nov 14, 2022 21:51 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 31,449 | $0.00 | $31.45 |
DisclosureSEC source: 0001093557-22-000173 · edgardoc.xml · nonDerivative · entry 1 Naganathan Girish · CIK 0001949138 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,449 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in four equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 31,449 unvested restricted stock units, 31,449 of which were granted on November 8, 2022 and shall vest through November 8, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.